Reference health
Clinical Impact of Monoclonal Antibodies in the Treatment of High-Risk Patients with SARS-CoV-2 Breakthrough Infections: The ORCHESTRA Prospective Cohort Study
26/26 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 26 checked references that resolve
resolves10.1093/cid/ciab361
Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel
resolves10.1056/NEJMoa2108891
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
resolves10.1038/s41577-021-00662-4
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
resolves10.1093/cid/ciac066
Characteristics of Reported Deaths Among Fully Vaccinated Persons With Coronavirus Disease 2019—United States, January–April 2021
resolves10.1016/j.cmi.2021.06.036
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
resolves10.1001/jama.2021.0202
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
resolves10.1056/NEJMoa2035002
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
resolves10.1056/NEJMoa2107934
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
resolves10.1056/NEJMc2119407
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
resolves10.1038/s41586-021-04385-3
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
resolves10.1016/S1473-3099(20)30483-7
A minimal common outcome measure set for COVID-19 clinical research
resolves10.12688/wellcomeopenres.16661.2
Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch
resolves10.1016/S2666-5247(21)00306-2
Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
resolves10.1016/j.blre.2022.100931
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research
resolves10.1016/j.mayocp.2021.11.017
Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
resolves10.1093/infdis/jiab570
Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities
resolves10.15585/mmwr.mm7032e3
Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021
resolves10.1056/NEJMoa2113017
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
resolves10.1016/S2468-1253(22)00005-X
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
resolves10.1182/blood.2021011568
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
resolves10.1093/cid/ciab381
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
resolves10.1038/s41586-021-04389-z
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
resolves10.7554/eLife.79639.sa2
Author response: Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
The 4 references without a DOI — listed, not checked
no DOI — not checkedCoburn, S.B., Humes, E., Lang, R., Stewart, C., Hogan, B.C., Gebo, K.A., Napravnik, S., Edwards, J.K., Browne, L.E., and Park, L.S. (medRxiv, 2021). COVID-19 infections post-vaccination by HIV status in the United States, medRxiv, in press.
no DOI — not checkedCenters for Disease Control and Prevention (2022, May 27). Public Health Investigations of COVID-19 Vaccine Breakthrough Cases. Case Investigation Protocol, Available online: https://www.cdc.gov/vaccines/covid-19/downloads/COVID-vaccine-breakthrough-case-investigations-Protocol.pdf.
no DOI — not checkedCenters for Disease Control and Prevention (2022, May 27). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, Available online: https://www.covid19treatmentguidelines.nih.gov/.
no DOI — not checkedWorld Health Organization (2022, May 27). WHO Expert Committee on Biological Standardization: Seventy-Fourth Report. Available online: https://www.who.int/publications/i/item/9789240046870.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.3390/biomedicines10092063"><img src="https://citestamp.com/citestamped/10.3390/biomedicines10092063/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.3390/biomedicines10092063)